You just read:

XARELTO® (rivaroxaban) Significantly Reduced the Risk of Overall Strokes and the Most Severe Strokes and Was Associated with Fewer Stroke-Related Deaths in the Real World Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Mar 18, 2019, 08:30 ET